FDA accepts Alvotech AVT80 biosimilar BLA
Analysis based on 10 articles · First reported Aug 31, 2026 · Last updated Aug 31, 2026
The FDA acceptance is a positive regulatory milestone for Alvogen, potentially strengthening its biosimilar pipeline and competitive position. It may also benefit Teva through commercialization rights, while increasing competitive pressure on the reference product Entyvio.
Alvogen announced that the United States — Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio (vedolizumab) for subcutaneous administration. AVT80 is developed and manufactured by Alvogen under a partnership with Sun Pharma, which will handle commercialization. The BLA submission is supported by analytical, pharmacokinetic, and immunogenicity data, including a pivotal pharmacokinetic study that met all primary endpoints. AVT80 complements AVT16, an intravenous biosimilar candidate whose BLA was accepted in May 2026. The European Union — European Medicines Agency has also validated a Marketing Authorization Application covering both candidates. If approved, AVT80 would expand biosimilar options for ulcerative colitis and Crohn's disease patients in the U.S.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard